Koyfin Home > Directory > Health Care > Intercept Pharmaceuticals > Gross Margin

Intercept Pharmaceuticals Gross Margin Chart (ICPT)

Intercept Pharmaceuticals annual/quarterly Gross Margin from 2011 to 2020. Gross margin is a company's total sales revenue minus its cost of goods sold (COGS), divided by total sales revenue, expressed as a percentage. The higher the percentage, the more the company retains on each dollar of sales, to service its other costs and debt obligations.
  • Intercept Pharmaceuticals Gross Margin for the quarter ending September 09, 2020 was $98m a 1.19% increase of 1m year over year
  • Intercept Pharmaceuticals Gross Margin for the last 12 months ending September 09, 2020 was $98m a -0.68% decrease of -1m year over year
  • Intercept Pharmaceuticals Annual Gross Margin for 2019 was $98m a -0.28% decrease of 0m from 2018
  • Intercept Pharmaceuticals Annual Gross Margin for 2018 was $99m a -0.36% decrease of 0m from 2017
  • Intercept Pharmaceuticals Annual Gross Margin for 2017 was $99m a -1.06% decrease of -1m from 2016
Other Margins & Efficiency Metrics:
  • Intercept Pharmaceuticals EBITDA Margin for the quarter ending December 12, 2018 was $-152m a -36.16% increase of 55m year over year
  • Intercept Pharmaceuticals Return on Capital % for the quarter ending September 09, 2018 was -28.58 a -108.87% increase of 31.11 year over year
  • Intercept Pharmaceuticals Return on Equity % for the quarter ending September 09, 2018 was -175.89 a -126.61% increase of 222.69 year over year
View Chart On Koyfin

Quarterly ICPT Gross Margin Data

09/2020$98m
06/2020$98m
03/2020$99m
12/2019$97m
09/2019$99m
06/2019$99m
03/2019$99m
12/2018$98m
09/2018$99m
06/2018$98m

Annual ICPT Gross Margin Data

2019$98m
2018$99m
2017$99m
2016$100m
2015$100m
2014$100m
2013$100m
2012$100m
2011$100m